Clinical evidence for psychedelic-assisted therapy is mounting.
This course summarizes the clinical evidence for psychedelic-assisted therapy in mental health and substance use treatment. It reviews safety, tolerability, and efficacy findings from studies on multiple psychedelic compounds in clinical settings with therapeutic oversight.
Details
Enrollment
Course Overview
This course presents a review of clinical research on psychedelic-assisted therapy, focusing on evidence for safety, tolerability, and effectiveness across several compounds. It includes a brief history of the field, summaries of findings by condition, and considerations for future research and adoption. The source material highlights evidence from more than 200 peer-reviewed studies and discusses outcomes reported for MDMA, psilocybin, ketamine, and other psychedelic compounds. It also outlines recommendations related to FDA approval, access, payer coverage, and public investment in research. The content is most relevant for clinicians, behavioral health professionals, researchers, and policy audiences seeking an overview of the current evidence base for psychedelic-assisted therapy.
Who is this for?
Clinicians, behavioral health professionals, researchers, and policy audiences interested in psychedelic-assisted therapy.
About the Provider
U.S. national public health agency for behavioral health policy and surveillance, including hallucinogen and ketamine epidemiology in national datasets.
View Substance Abuse and Mental Health Services Administration (SAMHSA) profileCourse Details
- PricePrice on request
- FormatSelf-paced
- Lifecycle statusNo New Dates
- SkillsIntegrationKetamine-Assisted TherapyPsilocybin TherapyMDMA-Assisted TherapyInterpreting clinical evidenceUnderstanding psychedelic-assisted therapyReviewing safety and tolerability dataComparing treatment outcomesAssessing research summariesUnderstanding policy and access considerationsInterpret clinical evidence on psychedelic-assisted therapyReview safety and tolerability findingsSummarize efficacy outcomes across conditionsCompare psychedelic-assisted therapy with treatment as usual
- Categories
Related Courses
View all coursesAdd Spravato® to Your Practice with Our 8-Phases Implementation Roadmap
By Ketamine Academy
Spravato FastTrack is an implementation course for clinics that want to add Spravato (esketamine) services. It covers REMS certification, procurement, prior authorization, billing, documentation, and related operational steps.
Are Ketamine Clinics Paving the Way for Legal Psychedelic Therapy?
By Double Blind
An article examining whether ketamine clinics could serve as a model for future legal psychedelic therapy. It discusses current ketamine clinic practices, emerging regulation questions, and how clinics are preparing for MDMA and psilocybin services.
Certificate in Psychedelic-Assisted Therapies & Research | CIISCIIS LogoCIIS Logo
By California Institute of Integral Studies (CIIS)
A 12-month certificate in psychedelic-assisted therapies and research housed in the CIIS Center for Psychedelic Therapies and Research. The program offers hybrid or online training covering clinical competencies, research, ethics, and culturally informed approaches.
Next cohort: Jul 13, 2026